7-2-1
7-2-1 is the podcast of the Foundation for Women & Girls with Blood Disorders (FWGBD).
Dr. Sweta Gupta has a passion for taking care of young women with bleeding disorders and heavy menstrual bleeding. 7-2-1 tackles some of the most pressing questions about periods and heavy menstrual bleeding faced by both healthcare providers and their patients: What is normal vs. heavy menstrual bleeding? Demystifying IUDS (LARCS). When should I see a specialist about my periods?
Join Dr. Gupta as she engages with the right expert(s) to help answer these questions. Each episode features conversations with leading medical experts, patients, and others who are involved in the field of blood disorders affecting women and girls. “The goal of this podcast is to provide engaging and useful content to healthcare providers, their patients, and others interested in learning more about this topic. The format of a podcast allows us to go more in-depth on these topics that are so critically important to healthcare professionals and our patients,” says Dr. Sweta Gupta, Pediatric Hematologist.
7-2-1
Special Edition – How New Gene Therapies for SCD May Impact Women’s Fertility
As we closed 2023, the Food and Drug Administration (FDA) approved two gene therapies to treat sickle cell disease (SCD). These potential curative therapies include CASGEVY™ (exagamglogene autotemcel [exa-cel]) from Vertex Pharmaceuticals Incorporated and CRISPER Therapeutics, and LYFGENIATM from bluebirdbio. While there is a lot of excitement for these advances, the impacts of these therapies are not currently known. Like with many therapies, the impact on women and their future fertility are among the unknowns and are areas of concern for individuals living with sickle cell disease and their healthcare providers.
Please join 7-2-1 for this special edition episode, How New Gene Therapies for SCD May Impact Women’s Fertility, with WGSCD LAN Chair, Dr. Alecia Nero, and special guest, Dr. Kelly Acharya, a Reproductive Endocrinologist, and Infertility Specialist with Duke Health. Together, they discuss the areas of concern for women and girls living with SCD and consider what the future may hold for those who are able to receive these life-changing treatments so that they may stay informed in the decision-making process.